In fact, patients on sitagliptin monotherapy had the shortest history of type 2 diabetes among groups (8.66 years for sitagliptin monotherapy, 11.8 years for sitagliptin-SU group and 11.2 years in sitagliptin-other OHA and/or insulin group). Here, INS is linked to type 2 diabetes mellitus.